Expression of Membrane-Bound Mucins and p63 in Distinguishing Mucoepidermoid Carcinoma from Papillary Cystadenoma

Emily A. Lanzel, Ali Pourian, Saulo Sousa Melo, Kim A. Brogden, John W. Hellstein

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The aim of this study was to compare the immunoexpression of epithelial mucins (MUCs) in salivary duct cysts, papillary cystadenomas, and mucoepidermoid carcinomas and to evaluate if any of these markers could be useful for differentiating between mucoepidermoid carcinoma and papillary cystadenoma. We also sought to validate the p63 expression pattern found to differentiate between mucoepidermoid carcinoma and papillary cystadenoma. Immunoexpression of MUC1, MUC2, MUC4, MUC7, and p63 was studied and quantified in 22 mucoepidermoid carcinomas, 12 papillary cystadenomas, and 3 salivary duct cysts. The immunohistochemical evaluation was collectively performed by 3 oral pathologists. Scores and trends in proportions were assessed using the nonparametric Wilcoxon–Mann–Whitney rank sum test. Mucoepidermoid carcinomas, papillary cystadenomas, and salivary duct cysts demonstrated variable MUC expression patterns. All tumors were positive for p63 immunoexpression with p63 labeling in salivary duct cysts and papillary cystadenomas (15/15) limited to the basal layers of the cystic spaces, whereas in mucoepidermoid carcinomas (22/22) the p63 labeling extended throughout the suprabasal layers (p < 0.001). This study adds more confirmatory data to validate that the reactivity pattern of p63 protein can be used in distinguishing between papillary cystadenoma and low-grade mucoepidermoid carcinoma. Although positive reactivity in a tumor with MUC1 and MUC4 was inconclusive, negative reactivity suggests the diagnosis of a benign PC or SDC.

Original languageEnglish (US)
Pages (from-to)521-526
Number of pages6
JournalHead and Neck Pathology
Volume10
Issue number4
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Papillary Cystadenoma
Mucoepidermoid Carcinoma
Mucins
Salivary Ducts
Membranes
Cysts
Papillary Carcinoma
Nonparametric Statistics
Neoplasms

Keywords

  • Immunohistochemistry
  • Mucins
  • Mucoepidermoid carcinoma
  • Papillary cystadenoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Otorhinolaryngology
  • Oncology

Cite this

Expression of Membrane-Bound Mucins and p63 in Distinguishing Mucoepidermoid Carcinoma from Papillary Cystadenoma. / Lanzel, Emily A.; Pourian, Ali; Sousa Melo, Saulo; Brogden, Kim A.; Hellstein, John W.

In: Head and Neck Pathology, Vol. 10, No. 4, 01.12.2016, p. 521-526.

Research output: Contribution to journalArticle

Lanzel, Emily A. ; Pourian, Ali ; Sousa Melo, Saulo ; Brogden, Kim A. ; Hellstein, John W. / Expression of Membrane-Bound Mucins and p63 in Distinguishing Mucoepidermoid Carcinoma from Papillary Cystadenoma. In: Head and Neck Pathology. 2016 ; Vol. 10, No. 4. pp. 521-526.
@article{2608f85d35f64df7bd0e045368613aa0,
title = "Expression of Membrane-Bound Mucins and p63 in Distinguishing Mucoepidermoid Carcinoma from Papillary Cystadenoma",
abstract = "The aim of this study was to compare the immunoexpression of epithelial mucins (MUCs) in salivary duct cysts, papillary cystadenomas, and mucoepidermoid carcinomas and to evaluate if any of these markers could be useful for differentiating between mucoepidermoid carcinoma and papillary cystadenoma. We also sought to validate the p63 expression pattern found to differentiate between mucoepidermoid carcinoma and papillary cystadenoma. Immunoexpression of MUC1, MUC2, MUC4, MUC7, and p63 was studied and quantified in 22 mucoepidermoid carcinomas, 12 papillary cystadenomas, and 3 salivary duct cysts. The immunohistochemical evaluation was collectively performed by 3 oral pathologists. Scores and trends in proportions were assessed using the nonparametric Wilcoxon–Mann–Whitney rank sum test. Mucoepidermoid carcinomas, papillary cystadenomas, and salivary duct cysts demonstrated variable MUC expression patterns. All tumors were positive for p63 immunoexpression with p63 labeling in salivary duct cysts and papillary cystadenomas (15/15) limited to the basal layers of the cystic spaces, whereas in mucoepidermoid carcinomas (22/22) the p63 labeling extended throughout the suprabasal layers (p < 0.001). This study adds more confirmatory data to validate that the reactivity pattern of p63 protein can be used in distinguishing between papillary cystadenoma and low-grade mucoepidermoid carcinoma. Although positive reactivity in a tumor with MUC1 and MUC4 was inconclusive, negative reactivity suggests the diagnosis of a benign PC or SDC.",
keywords = "Immunohistochemistry, Mucins, Mucoepidermoid carcinoma, Papillary cystadenoma",
author = "Lanzel, {Emily A.} and Ali Pourian and {Sousa Melo}, Saulo and Brogden, {Kim A.} and Hellstein, {John W.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s12105-016-0735-4",
language = "English (US)",
volume = "10",
pages = "521--526",
journal = "Head and Neck Pathology",
issn = "1936-055X",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Expression of Membrane-Bound Mucins and p63 in Distinguishing Mucoepidermoid Carcinoma from Papillary Cystadenoma

AU - Lanzel, Emily A.

AU - Pourian, Ali

AU - Sousa Melo, Saulo

AU - Brogden, Kim A.

AU - Hellstein, John W.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The aim of this study was to compare the immunoexpression of epithelial mucins (MUCs) in salivary duct cysts, papillary cystadenomas, and mucoepidermoid carcinomas and to evaluate if any of these markers could be useful for differentiating between mucoepidermoid carcinoma and papillary cystadenoma. We also sought to validate the p63 expression pattern found to differentiate between mucoepidermoid carcinoma and papillary cystadenoma. Immunoexpression of MUC1, MUC2, MUC4, MUC7, and p63 was studied and quantified in 22 mucoepidermoid carcinomas, 12 papillary cystadenomas, and 3 salivary duct cysts. The immunohistochemical evaluation was collectively performed by 3 oral pathologists. Scores and trends in proportions were assessed using the nonparametric Wilcoxon–Mann–Whitney rank sum test. Mucoepidermoid carcinomas, papillary cystadenomas, and salivary duct cysts demonstrated variable MUC expression patterns. All tumors were positive for p63 immunoexpression with p63 labeling in salivary duct cysts and papillary cystadenomas (15/15) limited to the basal layers of the cystic spaces, whereas in mucoepidermoid carcinomas (22/22) the p63 labeling extended throughout the suprabasal layers (p < 0.001). This study adds more confirmatory data to validate that the reactivity pattern of p63 protein can be used in distinguishing between papillary cystadenoma and low-grade mucoepidermoid carcinoma. Although positive reactivity in a tumor with MUC1 and MUC4 was inconclusive, negative reactivity suggests the diagnosis of a benign PC or SDC.

AB - The aim of this study was to compare the immunoexpression of epithelial mucins (MUCs) in salivary duct cysts, papillary cystadenomas, and mucoepidermoid carcinomas and to evaluate if any of these markers could be useful for differentiating between mucoepidermoid carcinoma and papillary cystadenoma. We also sought to validate the p63 expression pattern found to differentiate between mucoepidermoid carcinoma and papillary cystadenoma. Immunoexpression of MUC1, MUC2, MUC4, MUC7, and p63 was studied and quantified in 22 mucoepidermoid carcinomas, 12 papillary cystadenomas, and 3 salivary duct cysts. The immunohistochemical evaluation was collectively performed by 3 oral pathologists. Scores and trends in proportions were assessed using the nonparametric Wilcoxon–Mann–Whitney rank sum test. Mucoepidermoid carcinomas, papillary cystadenomas, and salivary duct cysts demonstrated variable MUC expression patterns. All tumors were positive for p63 immunoexpression with p63 labeling in salivary duct cysts and papillary cystadenomas (15/15) limited to the basal layers of the cystic spaces, whereas in mucoepidermoid carcinomas (22/22) the p63 labeling extended throughout the suprabasal layers (p < 0.001). This study adds more confirmatory data to validate that the reactivity pattern of p63 protein can be used in distinguishing between papillary cystadenoma and low-grade mucoepidermoid carcinoma. Although positive reactivity in a tumor with MUC1 and MUC4 was inconclusive, negative reactivity suggests the diagnosis of a benign PC or SDC.

KW - Immunohistochemistry

KW - Mucins

KW - Mucoepidermoid carcinoma

KW - Papillary cystadenoma

UR - http://www.scopus.com/inward/record.url?scp=84973652808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973652808&partnerID=8YFLogxK

U2 - 10.1007/s12105-016-0735-4

DO - 10.1007/s12105-016-0735-4

M3 - Article

VL - 10

SP - 521

EP - 526

JO - Head and Neck Pathology

JF - Head and Neck Pathology

SN - 1936-055X

IS - 4

ER -